1256P Three courses of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective phase II clinical trial

• DOI: 10.1016/j.annonc.2022.07.1374
• Publication Date: 2022-09-13T19:01:04Z
• Authors: G. Yang; X. Sun; H. Yang; G. Luo; Y. Zheng; M. Huang; Z. Wang; P. Cai; H. He; J. Xiang; M. Cai; J. Fu; Q. Liu; H. Yi; J. Zhong; Y. Huang; Q. Guo; X. Zhang
• Keywords: Clinical endpoint; Neoadjuvant Therapy; Regimen; Chemotherapy regimen